-
-
-
-
-
-
-
Kamada Reports Strong Third Quarter and Nine Month 2025 Financial Results with over 30% Year-over-Year Profitability Growth
-
-
-
-
-
-
-
Kamada Announces FDA Approval of its Plasma Collection Center in Houston, Texas
-
-
-
-
-
-
-
Kamada Updates on Withholding Tax Procedures on Previously Announced Special Cash Dividend to Shareholders
-
-
-
-
-
-
-
Kamada to Announce Fourth Quarter and Fiscal Year 2024 Financial Results on March 5, 2025
-
-
-
-
-
-
-
Kamada Reports Strong First Quarter 2024 Financial Results with Year-Over-Year Top-Line Growth of 23% and a 96% Increase in Profitability; Raises Full-Year Financial Guidance
-
-
-
-
-
-
-
Kamada Issues 2023 CEO Letter to Shareholders
-
-
-
-
-
-
-
STADA and Alvotech broaden European patients’ options by launching Hukyndra® high-concentration, citrate-free adalimumab
-
1,155,343 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

